Searched for
RADIOPHARMACEUTICALS
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsAs far as India is concerned, the biggest pain point from the US-Iran war in the Gulf region has been the spike in the prices of not only o...- Aurobindo Pharma arm CuraTeQ gets Health Canada nod for biosimilarAurobindo Pharma announced a significant development today. Its subsidiary, CuraTeQ Biologics, has received a compliance notice from Health...
- Global Markets | Australian shares slide as US-Iran talks fail, risk appetite soursAustralian shares declined as collapsed U.S.-Iran peace talks and a U.S. blockade of Iranian ports soured market sentiment. The S&P/ASX 200...
- Aurobindo Pharma’s Dyrupeg faces Health Canada compliance noticeCuraTeQ Biologics, a part of Aurobindo Pharma, has secured a crucial approval from Health Canada for its biosimilar drug Dyrupeg. This medi...
- AstraZeneca to buy fusion for $2 billionThe deal gives AstraZeneca a foothold in the radiopharmaceutical drugs market, which has seen increasing investor interest since 2021 when ...
- Jubilant Pharmova sells stake in Sofie Biosciences for $139.4 millionJPL holds a 25.8% stake in Sofie Biosciences, which it acquired through its Singapore-based subsidiary Jubilant Pharma in November 2020 for...
- BRICS Nuclear medicine experts brainstorm in Moscow for future solutionsThe event was attended by the heads and leading scientists of the largest research medical centers, manufacturers of medical radioisotopes ...
- Jubilant Pharmova Q1 Results: Net profit dips 87% YoY to Rs 6 croreTotal expenses in the first quarter were at Rs 1,568.9 crore, as compared to Rs 1,393.8 crore in the corresponding period a year ago.
- In-principle approval accorded to Jaitapur site for setting up 6 nuclear power reactors: GovtIn-principle approval has been accorded to a site in Maharashtra's Jaitapur for setting up six nuclear power reactors of 1,650 MW each in t...
- Stock pick of the week: Jubilant Life Sciences offers long-term growth say analystsSharp stock price correction, strong growth rates, focus on the growing speciality pharma segment, a bouquet of niche products, among other...
- Jubilant Life Sciences plans Rs 550-cr capex in FY19Pharma company Jubilant Life Sciences is planning to invest Rs 300 crore in research and development (R&D) in FY19.
- Jubilant Pharma completes Triad's US radiopharmacy acquisitionThe acquired radiopharmacies will continue to operate independently under the brand name of Triad Isotopes.
- Jubilant Life to buy Triad Isotopes' radio-pharmacy businessThe acquisition will be funded through JPL's internal accruals and is likely to be earnings accretive in the first full year of operations,...
- Jubilant Life Sciences announces price hike of up to 15%Jubilant Life Sciences is engaged in pharmaceuticals, life science ingredients and drug discovery solutions.
- Jubilant Life plans to raise up to Rs 1,300 croreDrug firm Jubilant Life Sciences' board will meet on Thursday to consider a proposal to raise about Rs 1,300 crore through issuance of secu...
- CCS upsets Fortis’ RadLink sale plan to Medi-Rad AssociatesFortis said it will explore other “value unlocking opportunities” for RadLink, a provider of outpatient diagnostic imaging, nuclear medicin...
- Jubilant Life Sciences Q3 net loss at Rs 11.16 croreIts net sales stood at Rs 1,430.25 crore during the period, marginal increase of 0.18 per cent per cent compared to Rs 1,427.65 crore y-o-y.
- Siemens to make nuclear medicines at Indian plantsGermany’s Siemens AG is finalising plans to manufacture radiopharmaceuticals (nuclear medicines) in India.
- Jubilant Organosys completes acquisition of Canadian firmPharmaceutical firm Jubilant Organosys has completed the acquisition of Canada-based Draxis Speciality Pharmaceuticals Inc for about Rs 1,0...
- Jubilant Organosys acquires Canada's Draxis for $255 mnJubilant Organosys Ltd and DRAXIS Health Inc. have entered into an agreement whereby a wholly-owned subsidiary of Jubilant will acquire all...
Load More
